TABLE 1.

OS within KRAS-variant patients by as-treated cetuximab

	No Cetuximab		Cetuximab
Time (years)	% Alive (95% CI)	No. of patients at risk	% Alive (95% CI)	No. of patients at risk
0	100% (N/A)	34	100% (N/A)	22
1	84.8% (67.4–93.4)	28	59.1% (36.1–76.2)	13
2	54.5% (36.3–69.6)	18	50.0% (28.2–68.4)	11
3	27.3% (13.6–42.9)	9	39.0% (18.5–59.1)	6
4	21.2% (9.4–36.3)	7	39.0% (18.5–59.1)	6
5	17.7% (6.9–32.5)	5	24.4% (7.4–46.5)	3
Dead/Total	29/34		15/22
Median survival time (95% CI)	2.4 (1.4–2.5)		1.9 (0.8–4.9)
HR (95% CI)	0.92 (0.49–1.74)
P a	0.9418

^aTwo-sided log-rank, stratified by radiation level (>51 Gy–≤66 Gy vs. >66 Gy).